UBS Group’s Aevi Genomic Medicine, Inc. GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-198,732
| Closed | -$29K | – | 7564 |
|
|
2019
Q4 | $29K | Buy |
198,732
+129,287
| +186% | +$18.9K | ﹤0.01% | 5616 |
|
|
2019
Q3 | $11K | Buy |
69,445
+24,809
| +56% | +$3.93K | ﹤0.01% | 6174 |
|
|
2019
Q2 | $7K | Sell |
44,636
-32,396
| -42% | -$5.08K | ﹤0.01% | 6410 |
|
|
2019
Q1 | $15K | Buy |
77,032
+72,032
| +1,441% | +$14K | ﹤0.01% | 5734 |
|
|
2018
Q4 | $4K | Sell |
5,000
-3,688
| -42% | -$2.95K | ﹤0.01% | 6746 |
|
|
2018
Q3 | $10K | Buy |
8,688
+7,688
| +769% | +$8.85K | ﹤0.01% | 6268 |
|
|
2018
Q2 | $1K | Hold |
1,000
| – | – | ﹤0.01% | 6947 |
|
|
2018
Q1 | $2K | Sell |
1,000
-6,503
| -87% | -$13K | ﹤0.01% | 6686 |
|
|
2017
Q4 | $9K | Buy |
7,503
+2,660
| +55% | +$3.19K | ﹤0.01% | 6150 |
|
|
2017
Q3 | $6K | Buy |
4,843
+2,799
| +137% | +$3.47K | ﹤0.01% | 6258 |
|
|
2017
Q2 | $2K | Sell |
2,044
-6,411
| -76% | -$6.27K | ﹤0.01% | 6475 |
|
|
2017
Q1 | $15K | Buy |
8,455
+2,389
| +39% | +$4.24K | ﹤0.01% | 5442 |
|
|
2016
Q4 | $31K | Buy |
6,066
+1,340
| +28% | +$6.85K | ﹤0.01% | 5290 |
|
|
2016
Q3 | $27K | Buy |
4,726
+2,976
| +170% | +$17K | ﹤0.01% | 5168 |
|
|
2016
Q2 | $10K | Hold |
1,750
| – | – | ﹤0.01% | 5918 |
|
|
2016
Q1 | $8K | Sell |
1,750
-1,963
| -53% | -$8.97K | ﹤0.01% | 5956 |
|
|
2015
Q4 | $23K | Buy |
3,713
+763
| +26% | +$4.73K | ﹤0.01% | 5451 |
|
|
2015
Q3 | $23K | Hold |
2,950
| – | – | ﹤0.01% | 5356 |
|
|
2015
Q2 | $18K | Sell |
2,950
-9,455
| -76% | -$57.7K | ﹤0.01% | 5595 |
|
|
2015
Q1 | $100K | Buy |
12,405
+12,205
| +6,103% | +$98.4K | ﹤0.01% | 4193 |
|
|
2014
Q4 | $1K | Buy |
+200
| New | +$1K | ﹤0.01% | 6713 |
|